

Certificate of Analysis for NR-55573

Klebsiella pneumoniae, Strain MRSN 564304

Catalog No. NR-55573

This reagent is the tangible property of the U.S. Government.

Product Description:

Klebsiella pneumoniae (K. pneumoniae), strain MRSN 564304 was isolated in 2018 from a human urine sample in North America as part of a global surveillance program. NR-55573 was deposited as a multi-drug resistance (MDR) strain sensitive to amikacin, ceftazidime/avibactam, ceftolozane/tazobactam, ciprofloxacin, ertapenem, gentamicin, imipenem, levofloxacin, meropenem, piperacillin/tazobactam and tigecycline, intermediate to aztreonam and ceftazidime and resistant to ampicillin/sulbactam, cefepime, ceftriaxone, tetracycline, trimethoprim/sulfamethoxazole and tobramycin. NR-55573 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. The material from the initial growth was passaged once in Tryptic Soy broth for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70051116 Manufacturing Date: 30MAR2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream
Motility (wet mount)	Report results	Non-motile
VITEK® 2 (GN card)	K. pneumoniae (≥ 89%)	K. pneumoniae (99%)
Antibiotic Susceptibility Profile ^{1,2}		
Amikacin	Sensitive	Sensitive (≤ 2 μg/mL)
Ampicillin/sulbactam	Resistant	Resistant (≥ 32 µg/mL)
Aztreonam	Intermediate	Intermediate (8 µg/mL)
Cefepime	Resistant	Sensitive (2 µg/mL) ³
Ceftazidime	Intermediate	Sensitive (4 µg/mL) ⁴
Ceftazidime/avibactam	Sensitive	Sensitive (0.25 to 0.5 µg/mL)
Ceftolozane/tazobactam	Sensitive	Sensitive (0.38 μg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (0.75 to1 µg/mL)
Ertapenem	Sensitive	Sensitive (≤ 0.5 μg/mL)
Gentamicin	Sensitive	Sensitive (≤ 1 μg/mL)
Imipenem	Sensitive	Sensitive (0.25 µg/mL)
Levofloxacin	Sensitive	Sensitive (1 μg/mL)
Meropenem	Sensitive	Sensitive (≤ 0.25 µg/mL)
Piperacillin/tazobactam	Sensitive	Sensitive (≤ 4 μg/mL)
Tetracycline	Resistant	Resistant (≥ 16 µg/mL)
Tigecycline	Sensitive	Sensitive (1 μg/mL) ⁵
Tobramycin	Resistant	Intermediate (6 µg/mL) ⁶
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene	≥ 99% sequence identity to	99.2% sequence identity to
(~ 1460 base pairs)	K. pneumoniae, strain MRSN 564304 (GenBank: JAGYCM010000081.1)	K. pneumoniae, strain MRSN 564304 (GenBank: JAGYCM010000081.1)

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Certificate of Analysis for NR-55573

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

/Sonia Bjorum Brower/ Sonia Bjorum Brower

02 JUN 2022

Lead Technical Writer or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²Antibiotic susceptibility was tested using a combination of bioMérieux VITEK®2 GN74 and ETEST®.

³K. pneumoniae, strain MRSN 564304 was deposited as resistant to cefepime, but showed a MIC of 2 μg/ mL (interpreted as sensitive) for this antibiotic during QC testing. Testing was performed in duplicate.

⁴The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

⁵MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

⁶K. pneumoniae, strain MRSN 564304 was deposited as resistant to tobramycin, but showed a MIC of 6 μg/mL (interpreted as intermediately resistant) for this antibiotic during QC testing. Testing was performed in duplicate.